Hepatic manifestations of inflammatory bowel diseases

• Published in: Liver international Vol. 37; no. 4; pp. 475 - 489
• Main Authors: Restellini, Sophie, Chazouillères, Olivier, Frossard, Jean‐Louis
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.04.2017
• Subjects: Abnormalities; Amyloidosis; Bowel disease; Cholangitis; Complications; Crohn's disease; Diagnostic systems; Diseases; Disorders; drug‐induced liver injury; Fatty liver; Granulomatous hepatitis; Hepatitis; hepatotoxicity; Humans; Immunoglobulin G; Incidence; inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - therapy; Intestine; Liver; Liver - pathology; Liver - physiopathology; liver disease; Liver diseases; Liver Diseases - etiology; Portal vein; primary sclerosing cholangitis; Thromboembolism; Thrombosis; Toxicity; Ulcerative colitis; drug-induced liver injury; liver disease; hepatotoxicity; inflammatory bowel disease; primary sclerosing cholangitis
• ISSN: 1478-3223; 1478-3231
• DOI: 10.1111/liv.13265

Inflammatory bowel diseases are associated with various hepatobiliary disorders, reported both in Crohn's disease and ulcerative colitis. They may occur at any moment in the natural course of the disease. The prevalence of liver dysfunction rises from 3% to 50% accordingly to definitions used in different studies. Fatty liver is considered as the most common hepatobiliary complication in inflammatory bowel diseases while primary sclerosing cholangitis is the most specific one. Less frequently, inflammatory bowel diseases‐associated hepatobiliary disorders include: autoimmune hepatitis/ primary sclerosing cholangitis overlap syndrome, IgG4‐associated cholangiopathy, primary biliary cholangitis, hepatic amyloidosis, granulomatous hepatitis, cholelithiasis, portal vein thrombosis and liver abscess. The spectrum of these manifestations varies according to the type of inflammatory bowel diseases. Treatments of inflammatory bowel diseases may cause liver toxicity, although incidence of serious complications remains low. However, early diagnosis of drug‐induced liver injury is of major importance as it affects future clinical management. When facing abnormal liver tests, clinicians should undertake a full diagnostic work‐up in order to determine whether the hepatic abnormalities are related to the inflammatory bowel diseases or not. Management of hepatic manifestations in inflammatory bowel diseases usually involves both hepatologists and gastroenterologists because of the complexity of some situations.